Ambys Medicines fetches $47m Series A extension

Ambys Medicines, a liver cell therapy platform, has secured a $47 million extension to its Series A financing, raising the total tally to $107 million.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this